AstraZeneca’s application for a subcutaneous (SC) version of its lupus therapy, Saphnelo, has been rejected by the U.S. Food and Drug Administration (FDA). Despite receiving a Complete Response Letter (CRL), the British pharmaceutical giant expects a final regulatory decision within the first half of 2026.
Details and background
The rejected application sought approval for a prefilled pen delivery system, enabling patients to self-administer the monoclonal antibody instead of undergoing monthly intravenous infusions at a clinic.
-
Company Response: AstraZeneca stated it has already provided the additional information requested by the FDA and remains committed to progressing the application as quickly as possible.
-
Global Standing: The European Medicines Agency (EMA) already approved the prefilled pen version in December 2025.
-
Clinical Evidence: Recent trial results demonstrated that the SC version offers clinical efficacy and safety profiles consistent with the intravenous form, significantly reducing disease activity and the need for oral corticosteroids.
Competitive landscape in Lupus treatment
Saphnelo currently competes with GSK’s Benlysta in the systemic lupus erythematosus (SLE) market. While Benlysta has offered a subcutaneous option since 2017 and maintains a dominant market share, AstraZeneca is pushing for approval of its self-administered version to enhance patient convenience and competitiveness.
SLE affects more than 3.4 million people worldwide, primarily women, leading to chronic symptoms and increased mortality risks. The evolution toward self-injectable treatments represents a significant shift in managing the disorder, moving away from a heavy reliance on oral corticosteroids toward more targeted, patient-friendly therapies.